

## Publikationsliste (2024-1993) (Univ.-Prof. Dr. Michael Huber):

- **Begutachtete Veröffentlichungen**

86. Capellmann, S., Kauffmann, M., Arock, M., **Huber, M.** (2024). *SR-BI regulates the synergistic mast cell response by modulating the plasma membrane-associated cholesterol pool.*

**The European Journal of Immunology**, in press. IF: 5.4

85. Ahmed, N., Preisinger, C., Wilhelm, T., **Huber, M.** (2024). *TurboID-based IRE1 interactome reveals participants of the ERAD machinery in the human mast cell leukemia cell line HMC-1.2.*

**Cells**, in press. IF: 6.0

84. Salimi, A., Schemionek-Reinders, M., **Huber, M.**, Vieri, M., Patterson, J. B., Alten, J., Brümmendorf, T. H., Kharabi Masouleh, B., and Appelmann, I. (2023). *XBP1 promotes NRAS<sup>G12D</sup> pre-B acute lymphoblastic leukemia through IL-7 receptor signaling and provides a therapeutic vulnerability for oncogenic RAS.*

**Journal of Cellular and Molecular Medicine**, 27: 3363-3377. IF: 5.3

83. Jacobi, H., Vieri, M., Bütow, M., Namasu, C. Y., Flüter, L., Costa, I. G., Maié, T., Lindemann-Docter, K., Chatain, N., Beier, F., **Huber, M.**, Wagner, W., Crysandt, M., Brümmendorf, T. H., Schemionek-Reinders, M. (2023). *Failure of treatment-free remission in CML patients presenting with myelofibrosis at diagnosis.*

**Frontiers in Pharmacology**, 14: 1212392. IF: 5.35

82. Langhammer, M., Ellermann, J., Jaquet, T., Horn, K., Christen, D., Uhl, F. M., Angel, M., Spohr, C., Feyerabend, T., Huber, J., Zeiser, R., Aumann, K., Koschmieder, S., **Huber, M.**, Schemionek-Reinders, M., Brummer, T., and Halbach, S. (2023). *Mast cell deficiency prevents BCR-ABL induced splenomegaly and cytokine elevation in a chronic-phase CML mouse model.*

**Leukemia**, 37: 1474-1484. IF: 12.897

81. Capellmann, S., Sonntag, R., Schüler, H., Meurer, S. K., Gan, L., Kauffmann, M., Horn, K., Königs-Werner, H., Weiskirchen, R., Liedtke, C., and **Huber, M.** (2023).

*Transformation of primary murine peritoneal mast cells by constitutive KIT activation is accompanied by loss of Cdkn2a/Arf expression.*

**Frontiers in Immunology**, 14: 1154416. IF: 8.786

80. Wilhelm, T., Toledo, M. A. S., Simons, I., Stuth, C., Mohta, V., Mülfarth, R., Nitsche, M., Maschke-Neuß, K., Schmitz, S., Kaiser, A., Arock, M., Zenke, M., and **Huber, M.** (2023). *Capitalizing on paradoxical activation of the MAPK pathway for treatment of Imatinib-resistant mast cell leukemia.*

**Haematological Oncology**, doi: 41: 520-534. IF: 3.3

79. Boukeileh, S., Darawshi, O., Shmuel, M., Mahameed, M., Wilhelm, T., Dipta, P., Forno, F., Praveen, B., **Huber, M.**, Levi-Schaffer, F., Tirosh, B. (2022). *Endoplasmic reticulum homeostasis regulates TLR4 expression and signaling in mast cells.*

**International Journal of Molecular Sciences**, 23: 11826. IF: 6.208

78. Arik, E., Heinisch, O., Bienert, M., Gubeljak, L., Slowik, A., Reich, A., Schulz, J. B., Wilhelm, T., **Huber, M.**, and Habib, P. (2022). *Erythropoietin enhances post-ischemic migration and phagocytosis and alleviates the activation of inflammasomes in human microglial cells.*

**Frontiers in Cellular Neuroscience**, 16: 915348. IF: 5.505

77. Kokott-Vuong, A., Jung, J., Fehr, A. T., Kirschfink, N., Noristani, R., Voigt, A., Reich, A., Schulz, J. B., **Huber, M.**, and Habib, P. (2021). *Increased post-hypoxic oxidative stress and activation of the PERK branch of the UPR in Trap1-deficient Drosophila melanogaster is abrogated by Metformin.*

**International Journal of Molecular Sciences**, 22: 11586. IF: 5.923

76. Heinisch, O., Zeyen, T., Goldmann, T., Prinz, M., **Huber, M.**, Jung, J., Arik, E., Habib, S., Slowik, A., Reich, A., Schulz, J. B., and Habib, P. (2022). *Erythropoietin abrogates post-ischemic activation of the NLRP3, NLRC4 and AIM2 inflammasomes in microglia/macrophages in a TAK1-dependent manner.*

**Translational Stroke Research**, 13: 462-482. IF: 6.829

75. Parting, O., Langer, S., Kuepper, M. K., Wessling, C. C. A., Li, S., Braunschweig, T., Chatain, N., Maié, T., Costa, I., Crysandt, M., **Huber, M.**, Brümmendorf, T. H., Koschmieder, S., and Schemionek, M. (2020). *Therapeutic inhibition of FcγRIIB signaling targets leukemic stem cells in chronic myeloid leukemia.*

**Leukemia**, 34: 2635-2647. IF: 9.944

74. Zeyen, T., Noristani, R., Habib, S., Heinisch, O., Slowik, A., **Huber, M.**, Schulz, J. B., Reich, A., and Habib, P. (2020). *Microglial-specific depletion of TAK1 is neuroprotective in the acute phase after ischemic stroke.*

**Journal of Molecular Medicine**, 98: 833-847. IF: 4.746

73. Mahameed, M., Boukeileh, S., Obiedat, A., Darawshi, O., Dipta, P., Rimon, A., McLennan, G., Fassler, R., Reichmann, D., Karni, R., Preisinger, C., Wilhelm, T., **Huber, M.**, and Tirosh, B. (2020). *Pharmacological induction of selective endoplasmic reticulum retention as a strategy for cancer therapy.*

**Nature Communications**, 11: 1304. IF: 11.880

72. Simonowski, A., Wilhelm, T., Habib, P., Zorn, C. N., and **Huber, M.** (2019). *Differential use of BTK and PLC in FcεRI- and KIT-mediated mast cell activation: a marginal role of BTK upon KIT activation.*

**BBA – Molecular Cell Research**, 1867: 118622. IF: 4.739

71. Habib, P., Stamm, A.-S., Schulz, J. B., Reich, A., Slowik, A., Capellmann, S., **Huber, M.**, and Wilhelm, T. (2019). *EPO and TMBIM3/GRINA promote the activation of the adaptive arm and counteract the terminal arm of the unfolded protein response after murine transient cerebral ischemia.*

**International Journal of Molecular Sciences**, 20: E5421. IF: 4.183

70. Elmaagacli, A. H., Jehn, C., Shikova, Y., **Huber, M.**, Salwender, H., Dahmash, F., Singh, A., Niggemann, C., and Vierbuchen, M. (2019). *Advanced systemic mastocytosis with strong expression of signaling lymphocyte activation marker family member 7 (SLAMF7) responsive to therapy with elotuzumab and lenalidomide.*

**Leukemia and Lymphoma**, 61: 485-487. IF: 2.674

69. Brown, P., **RELISH Consortium**, and Zhou, Y. (2019). *Large expert-curated database for benchmarking document similarity detection in biomedical literature search.*

**Database**, baz085. IF: 3.683 [**Huber, M.** is part of the RELISH Consortium]

68. Habib, P., Stamm, A.-S., Zeyen, T., Noristani, R., Slowik, A., Beyer, C., Wilhelm, T., **Huber, M.**, Komnig, D., Schulz, J. B., and Reich, A. (2019). *EPO regulates neuroprotective Transmembrane BAX Inhibitor-1 Motif-containing (TMBIM) family members GRINA and FAIM2 after cerebral ischemia-reperfusion injury.*

**Experimental Neurology**, 320: 112978. IF: 4.483

67. Mahameed, M., Wilhelm, T., Darawshi, O., Tommy, W., Chinthia, C., Schubert, T., Samali, A., Chevet, E., Eriksson, L. A., **Huber, M.**, and Tirosh, B. (2019). *The unfolded protein response modulators GSK2606414 and KIRA6 are potent KIT inhibitors.*

**Cell Death & Disease**, 10: 300. IF: 5.638

66. Zorn, C. N., Simonowski, A., and **Huber, M.** (2018). *Stimulus strength determines the BTK-dependence of the SHIP1-deficient phenotype in IgE/antigen-triggered mast cells.*

**Scientific Reports**, 8: 15467. IF: 4.122

65. Gast, M., Preisinger, C., Nimmerjahn, F., and **Huber, M.** (2018). *IgG-independent co-aggregation of Fc $\alpha$ RI and Fc $\gamma$ RIIB results in LYN- and SHIP1-dependent tyrosine phosphorylation of Fc $\gamma$ RIIB in murine bone marrow-derived mast cells.*

**Frontiers in Immunology**, 9: 1937. IF: 5.511

64. Klasen, C., Ziehm, T., **Huber, M.**, Asare, Y., Kapurniotu, A., Shachar, I., Bernhagen, J., and El Bounkari, O. (2018). *LPS-mediated cell surface expression of CD74 promotes the proliferation of B cells in response to MIF.*

**Cellular Signalling**, 46: 32-42. IF: 3.937

63. Wilhelm, T., Bick, F., Peters, K., Mohta, V., Tirosh, B., Patterson, J. B., Kharabi-Masouleh, B., and **Huber, M.** (2017). *Infliction of proteotoxic stresses by impairment of the unfolded protein response or proteasomal inhibition as a therapeutic strategy for mast cell leukemia.*

**Oncotarget**, 9: 2984-3000. IF: 5.168

62. Maler, M. D., Nielsen, P. J., Stichling, N., Cohen, I., Ruzsics, Z., Wood, C., Engelhard, P., Suomalainen, M., Gyory, I., **Huber, M.**, Müller-Quernheim, J., Schamel, W., Gordon, S., Jakob, T., Martin, S. F., Jahnen-Dechent, W., Greber, U., Freudenberg, M. A., and Fejer, G. (2017). *Key role of the scavenger receptor MARCO in mediating adenovirus infection and subsequent innate responses of macrophages.*

**mBio**, 8: e00670-17. IF: 6.975

61. Poplutz, M., Levikova, M., Lüscher-Firzlaff, J., Lesina, M., Algül, H., Lüscher, B., and **Huber, M.** (2017). *Endotoxin tolerance in mast cells, its consequences for IgE-mediated signalling, and the effects of BCL3 deficiency.*  
**Scientific Reports**, 7: 4534. IF: 4.259
60. Meurer, S. K., Neß, M., Weiskirchen, S., Kim, P., Tag, C. G., Kauffmann, M., **Huber, M.**, and Weiskirchen, R. (2016). Isolation of mature (peritoneum-derived) mast cells and immature (bone marrow-derived) mast cell precursors from mice.  
**PLoS ONE**, 11: e0158104. IF: 3.23
59. Nunes de Miranda, S. M., Wilhelm, T., **Huber, M.\***, and Zorn, C. N.\* (2016). *Differential Lyn-dependence of the SHIP1-deficient mast cell phenotype.*  
**Cell Communication and Signaling**, 14: 12. IF: 3.378
58. Zotz, J. S., Wölbing, F., Lassnig, C., Kauffmann, M., Schulte, U., Kolb, A., Whitelaw, B., Müller, M., Biedermann, T.\*, **Huber, M.\*** (2016). *CD13/aminopeptidase N is a negative regulator of mast cell activation.*  
**The FASEB Journal**, 30: 2225-2235. IF: 5.043
57. Kuhny, M., Hochdörfer, T., Ayata, C. K., Idzko, M., and **Huber, M.** (2014). *CD39 is a negative regulator of P2X<sub>7</sub>-mediated inflammatory cell death in mast cells.*  
**Cell Communication and Signaling**, 12: 40. IF: 4.67
56. Plum, L. M., Engelhardt, G., Hebel, S., Brieger, A., Nessel, A., Kaltenberg, J., Schwaneberg, U., **Huber, M.**, Rink, L., and Haase, H. (2014). *PTEN-inhibition by zinc ions augments interleukin-2-mediated Akt phosphorylation.*  
**Metallomics**, 6:1277-1287. IF: 4.1
55. Zorn, C. N., Pardo, J., Martin, P., Kuhny, M., Simon, M. M., and **Huber, M.** (2013) *Secretory lysosomes of mouse mast cells store and exocytose active caspase-3 in a strictly granzyme B-dependent manner.*  
**The European Journal of Immunology**, 43: 3209-3218. IF: 4.97
54. Fejer, G., Wegner, M., Györy, I., Cohen, I., Engelhard, P., Voronov, E., anke, T., Ruzsics, Z., Dölken, L., Prazeres da Costa, O., Branzk, N., **Huber, M.**, Prasse, A., Schneider, R., Apte, R. N., Galanos, C., and Freudenberg, M. A. (2013). *Self-renewing, non-transformed, GM-CSF-dependent, stable macrophage lines, a model to study tissue macrophage functions.*  
**Proceedings of the National Academy of Sciences USA**, E2191-E2198. IF: 9.70
53. Kundu, K., Costa, F., **Huber, M.**, Reth, M., Backofen, R. (2013). *Semi-supervised prediction of SH2-peptide interactions from imbalanced high-throughput data.*  
**PLoS ONE**, 8: e62732. IF: 4,092
52. Hochdörfer, T., Tiedje, C., Stumpo, D. J., Blackshear, P. J., Gaestel, M., and **Huber, M.** (2013). *LPS-induced production of TNF- $\alpha$  and IL-6 in mast cells is dependent on p38 but independent of TTP.*  
**Cellular Signaling**, 25: 1339-1347. IF: 4.058

51. Yousefi, O. S., Wilhelm, T., Maschke-Neuß, K., Kuhny, M., Martin, C., Molderings, G. J., Kratz, F., Hildenbrand, B., and **Huber, M.** (2013). *The 1,4-benzodiazepine Ro5-4864 (4-chlorodiazepam) suppresses multiple pro-inflammatory mast cell effector functions.*

**Cell Communication and Signaling**, 11:13. IF: 5.50

50. Haenisch, B., **Huber, M.**, Wilhelm, T., Steffens, M., and Molderings, G. J. (2013). *Investigation of potential mechanisms mediating the inhibitory effect of benzodiazepines on mast cell by gene expression profiling.*

**Life Sciences**, 92: 345-351. IF: 2.527

49. Marschall, J., Wilhelm, T., Schuh, W., and **Huber, M.** (2012). *MEK/Erk-based negative feedback mechanism involved in control of Steel Factor-triggered production of Krüppel-like factor 2 in mast cells.*

**Cellular Signalling**, 24: 879-888. IF: 4.058

48. Mukherjee, O., Weingarten, L., Padberg, I., Pracht, C., Sinha, R., Hochdörfer, T., Kuppig, T., Backofen, R., Reth, M., and **Huber, M.** (2012). *The SH2-domain of SHIP1 interacts with the SHIP1 C-terminus: impact on SHIP1/Ig- $\alpha$  interaction.*

**BBA – Molecular Cell Research**, 1823: 206-214. IF: 5.538

47. Keck, S., Müller, I., Fejer, G., Savic, I., Tchaptchet, S., Nielsen, P. J., Galanos, C., **Huber, M.\***, and Freudenberg, M. A\*. (2011). *Absence of TRIF signaling in LPS-stimulated murine mast cells.*

**The Journal of Immunology**, 186: 5478-5488. IF: 5.646

\*) equal contribution

46. Hochdörfer, T., Kuhny, M., Zorn, C. N., Hendriks, R. W., Vanhaesebroeck, B., Bohnacker, T., Krystal, G., and **Huber, M.** (2011). *Activation of the PI3K pathway increases TLR-induced TNF- $\alpha$  and IL-6 but reduces IL-1 $\beta$  production in mast cells.*

**Cellular Signalling**, 23: 866-875. IF: 4.094

45. Bartsch, I., Bläser, S., Röseler, S., Sandrock, K., Busse, A., **Huber, M.**, Rempp, H., Lieber, M., Horn, J., Brendle, C., and Zieger, B. (2010). *Human endothelial and platelet septin SEPT11: Cloning of novel variants and characterization of interaction partners.*

**Thrombosis and Haemostasis**, 104: 1201-1210. IF: 4.451

44. Orinska, Z., Föger, N., **Huber, M.**, Marschall, J., Mirgomizadeh, F., Du, X., Scheller, M., Rosenstiel, P., Goldmann, T., Bollinger, A., Beutler, B. A., and Bulfone-Paus, S. (2010). *I787 provides signals for c-Kit receptor internalization and functionality that control mast cell survival and development.*

**Blood**, 116: 2665-2675. IF: 10.555

43. Keck, S., Freudenberg, M., and **Huber, M.** (2010). *Activation of murine macrophages via TLR2 and TLR4 is negatively regulated by a Lyn/PI3K module and promoted by SHIP1.*

**The Journal of Immunology**, 184: 5809-5818. IF: 5.646

42. Fehrenbach, K., Lessmann, E., Zorn, C. N., Kuhny, M., Grochowoy, G., Krystal, G., Leitges, M., and **Huber, M.** (2009). *Steel Factor enhances supra-optimal antigen-induced interleukin-6 production from mast cells via activation of protein kinase C- $\beta$* . **The Journal of Immunology**, 182: 7897-7905. IF: 6.000
41. Grochowoy, G., Hermiston, M. L., Kuhny, M., Weiss, A., and **Huber, M.** (2009). *Requirement for CD45 in Fine-Tuning Mast Cell Responses Mediated by Different Ligand-Receptor Systems*. **Cellular Signalling**, 21: 1277-1286. IF: 4.305
40. Zorn, C. N., Keck, S., Hendriks, R. W., Leitges, M., Freudenberg, M. A., and **Huber, M.** (2009). *Bruton's tyrosine kinase is dispensable for the Toll-like receptor-mediated activation of mast cells*. **Cellular Signalling**, 21: 79-86. IF: 4.305
39. Minguet, S., Dopfer, E. P., Pollmer, C., Freudenberg, M. A., Galanos, C., Reth, M., **Huber, M.**, and Schamel, W. W. (2008). *Enhanced B cell activation mediated by TLR4 and BCR crosstalk*. **The European Journal of Immunology**, 38: 2475-2487. IF: 4.662
38. Molendijk, A. J., Ruperti, B., Singh, M., Dovzhenko, A., Ditengou, F. A., Milia, M., Westphal, L., Rosahl, S., Soellick, T.-R., Uhrig, J., Weingarten, L., **Huber, M.**, and Palme, K. (2008). *A cysteine-rich receptor-like kinase is predominantly expressed in vasculature and functions in Rop GTPase and brassinosteroid signaling*. **Plant Journal**, 53: 909-923. IF: 6.751
37. Ali, S., **Huber, M.**, Kollwe, C., Bischoff, S. C., Falk, W., and Martin, M. U. (2007). *The interleukin-1 receptor accessory protein is essential for interleukin-33 induced activation of T cells and mast cells*. **Proceedings of the National Academy of Sciences USA**, 104: 18660-18665. IF: 9.643
36. Grosse, J., Braun, A., Varga-Szabo, D., Beyersdorf, N., Schneider, B., Zeitlmann, L., Hanke, P., Schropp, P., Mühlstedt, S., Zorn, C., **Huber, M.**, Schmittwolf, C., Jagla, W., Yu, P., Kerkau, T., Schulze, H., Nehls, M., and Nieswandt, B. (2007). *An EF hand mutation in Stim1 causes premature platelet activation and bleeding in mice*. **Journal of Clinical Investigation**, 117: 3540-3550. IF: 15.754
35. Pardo, J., Wallich, R., Ebnet, K., Iden, S., Zentgraf, H., Martin, P., Ekiciler, A., Prins, A., Müllbacher, A., **Huber, M.**, and Simon, M. M. (2007). *Granzyme B is expressed in mouse mast cells in vivo and in vitro and causes delayed cell death independent of perforin*. **Cell Death & Differentiation**, 14: 1768-1779. IF: 7.463
34. Gibbs, B. F., R athling, A., **Huber, M.**, and Haas, H. (2007). *Substantial differences in the kinetics of histamine release from human basophils caused by varying strengths of IgE-dependent activators*. **Inflammation Research**, 56: S5-S6. IF: 1.485

33. Fehrenbach, K., Port, F., Grochoway, G., Kalis, C., Bessler, W., Galanos, C., Krystal, G., Freudenberg, M., and **Huber, M.** (2007). *Stimulation of mast cells via FcεR1 and TLR2: the type of ligand determines the outcome.* **Molecular Immunology**, 44: 2097-2104. IF: 4.768
32. Pracht, C., Minguet, S., Leitges, M., Reth, M., and **Huber, M.** (2007). *PKC-δ interacts with the B cell antigen receptor complex.* **Cellular Signalling**, 19: 715-722. IF: 4.887
31. Abraham, D., Oster, H., **Huber, M.**, and Leitges, M. (2007). *The expression pattern of three mast cell specific proteases during mouse development.* **Molecular Immunology**, 44: 732-740. IF: 4.768
30. Lessmann, E., Ngo, M., Leitges, M., Minguet, S., Ridgway, N. A., and **Huber, M.** (2007). *Oxysterol binding protein-related protein (ORP) 9 is a PDK-2 substrate and regulates Akt phosphorylation.* **Cellular Signalling**, 19: 384-392. IF: 4.887
29. Elis, W., Lessmann, E., Oelgeschlaeger, M., and **Huber, M.** (2006). *Mutations in the inter-SH2 domain of the regulatory subunit of phosphoinositide 3-kinase: effects on catalytic subunit binding and holoenzyme function.* **Biological Chemistry**, 387: 1567-1573. IF: 2.577
28. Gibbs, B. F., R athling, A., Zillikens, D., **Huber, M.**, and Haas, H. (2006). *Initial FcεRI-mediated signal strength plays a key role in regulating basophil signaling and deactivation.* **Journal of Allergy and Clinical Immunology**, 118: 1060-1067. IF: 7.667
27. Lessmann, E., Grochoway, G., Weingarten, L., Giesemann, T., Aktories, K., Leitges, M., Krystal, G., and **Huber, M.** (2006). *Insulin and Insulin-like growth factor-1 promote mast cell survival via activation of the phosphatidylinositol-3-kinase pathway.* **Experimental Hematology**, 34: 1532-1541. IF: 4.019
26. Bl aser, S., Rempp, H., R oseler, S., Bauer, H., Lieber, M., Pagenstecher, A., Lessmann, E., Weingarten, L., Busse, A., **Huber, M.**, and Zieger, B. (2006). *Human endothelial cell septins: SEPT11 is an interaction partner of SEPT5.* **Journal of Pathology**, 210: 103-110. IF: 6.213
25. Lessmann, E., Leitges, M., and **Huber, M.** (2006). *A redundant role of PKC-ε for mast cell signal transduction and effector function.* **International Immunology**, 18: 767-773. IF: 3.317
24. **Huber, M.\***, Kalis, C.\*, Keck, S., Jiang, Z., Georgel, P., Du, X., Shamel, L., Sovath, S., Mudd, S., Beutler, B., Galanos, C., and Freudenberg, M. (2006). *R-form LPS, the master key to the activation of TLR4/MD2 positive cells.* **The European Journal of Immunology**, 36: 701-711. IF: 4.876  
Featured in "In this issue", same issue, pp. 501-502.

23. Jiang, Z., Georgel, P., Du, X., Shamel, L., Sovath, S., Mudd, S., **Huber, M.**, Kalis, C., Keck, S., Galanos, C., Freudenberg, M., and Beutler, B. (2005). *CD14 is required for MyD88-independent LPS signaling*. **Nature Immunology**, 6: 565-570. IF: 27.586  
Featured in "News and Views" by P. J. Godowski in the same issue, pp. 544-546.
22. Gimborn, K., Lessmann, E., Kuppig, S., Krystal, G., and **Huber, M.** (2005). *SHIP down-regulates FcεR1-induced degranulation at supra-optimal IgE or antigen levels*. **The Journal of Immunology**, 174: 507-516. IF: 6.486
21. Minguet, S.\*, **Huber, M.\***, Rosenkranz, L., Schamel, W., Reth, M., and Brummer, T. (2005). *FRONTLINE: Adenosine and cAMP are potent inhibitors of the NF kappa B pathway downstream of immunoreceptors*. **The European Journal of Immunology**, 35: 31-41. IF: 5.005  
\*) equal contribution  
Featured in a Commentary by M. S. Hershfield in the same issue, pp. 25-30.
20. Elis, W., Reth, M., and **Huber, M.** (2004). *Functional folding of a cytoplasmic single-chain variable fragment and its use as elutable protein purification tag*. **Immunology Letters**, 92: 185-192. IF: 1.710
19. Renkl, A., Berod, L., Mockenhaupt, M., Idzko, M., Panther, E., Termeer, C., Elsner, P., **Huber, M.**, and Norgauer, J. (2004). *Distinct effects of sphingosine-1-phosphate, lysophosphatidic acid and histamine in human and mouse dendritic cells*. **International Journal of Molecular Medicine**, 13: 203-209. IF: 1.940
18. Leitges, M., Gimborn, K., Elis, W., Kalesnikoff, J., Hughes, M. R., Krystal, G., and **Huber, M.** (2002). *PKC-δ is a negative regulator of antigen-induced mast cell degranulation*. **Molecular and Cellular Biology**, 22: 3970-3980. IF: 9.836
17. Kalesnikoff, J., Baur, N., Leitges, M., Hughes, M. R., Damen, J. E., **Huber, M.**, and Krystal, G. (2002). *SHIP negatively regulates IgE+antigen-induced IL-6 production in mast cells by inhibiting NFκB activity*. **The Journal of Immunology**, 168: 4737-4746. IF: 7.650
16. Pracht, C., Gimborn, K., Reth, M., and **Huber, M.** (2002). *BCR mutants deficient in ligand-independent and more sensitive for ligand dependent signalling*. **The European Journal of Immunology** 32: 1614-1620. IF: 4.990
15. Scheid, M. P.\*, **Huber, M.\***, Damen, J. E., Hughes, M., Kang, V., Neilsen, P., Prestwich, G. D., Krystal, G., and Duronio, V. (2002). *Phosphatidylinositol(3,4,5)P<sub>3</sub> is essential but not sufficient for PKB activation: Phosphatidylinositol(3,4)P<sub>2</sub> is required for PKB phosphorylation at Ser473. Studies using cells from SHIP knockout mice*. **The Journal of Biological Chemistry** 277: 9027-9035. IF: 7.258  
\*) equal contribution



14. Leitges, M., Elis, W., Gimborn, K., and **Huber, M.** (2001). *Rottlerin-independent attenuation of pervanadate-induced tyrosine phosphorylation events by PKC- $\delta$  in hemopoietic cells.*  
**Laboratory Investigation** 81: 1087-1095. IF: 4.165
13. Kalesnikoff, J., **Huber, M.**, Damen, J. E., Bigg, C. M., Lam, V., Siraganian, R., and Krystal, G. (2001). *Monomeric IgE stimulates signaling pathways in mast cells that lead to cytokine production and cell survival.*  
**Immunity** 14: 801-811. IF: 21.083
12. **Huber, M.**, Hughes, M. R., and Krystal, G. (2000). *Thapsigargin-induced degranulation of mast cells is dependent on transient activation of phosphatidylinositol 3-kinase.*  
**The Journal of Immunology** 165: 124-133. IF: 7.145
11. Pasquet, J.-M., Quek, L., Stevens, C., Bobe, R., **Huber, M.**, Duronio, V., Krystal, G., and Watson, S. P. (2000). *PI3,4,5P<sub>3</sub> regulates Ca<sup>2+</sup> entry via Btk in platelets and megakaryocytes without increasing PLC activity.*  
**The EMBO Journal** 19: 2793-2802. IF: 13.973
10. Rabkin, S. W., **Huber, M.**, and Krystal, G. (1999). *Modulation of palmitate-induced cardiomyocyte cell death by interventions that alterate intracellular calcium.*  
**Prostaglandins Leukotrienes and Essential Fatty Acids** 61: 195-201. IF: 1.194
9. Rey-Ladino, J. A., **Huber, M.**, Liu, L., Damen, J. E., Krystal, G., and Takei, F. (1999). *The SH2-containing inositol-5'-phosphatase, SHIP, enhances LFA-1 (CD11a/CD18)-mediated cell adhesion and defines two signalling pathways of LFA-1 activation.*  
**The Journal of Immunology** 162: 5792-5799. IF: 7.166
8. **Huber, M.**, Watson K, Selinka, H.-C., Carthy, C. M., Klingel, K., McManus, B. M., and Kandolf, R. (1999). *Cleavage of RasGAP and Phosphorylation of Mitogen-Activated Protein Kinase in the Course of Coxsackievirus B3 Replication.*  
**The Journal of Virology** 73: 3587-3594. IF: 5.828
7. **Huber, M.**, Helgason, C. D., Damen, J. E., Scheid, M. P., Duronio, V., Humphries, R. K., and Krystal, G. (1998). *Targeted disruption of SHIP leads to steel factor induced degranulation of mast cells.*  
**The EMBO Journal** 17: 7311-7319. IF: 12.643
6. Klingel, K., Rieger, P., Mall, G., Selinka, H.-C., **Huber, M.**, and Kandolf, R. (1998). *Visualization of enteroviral replication in myocardial tissue by ultrastructural in situ hybridization: Identification of target cells and cytopathic effects.*  
**Laboratory Investigation** 78: 1227-1237. IF: 4.653
5. **Huber, M.**, Helgason, C. D., Damen, J. E., Liu, L., Humphries, R. K., and Krystal, G. (1998). *The src homology 2-containing inositol phosphatase (SHIP) is the gatekeeper of mast cell degranulation.*

**Proceedings of the National Academy of Sciences USA** 95: 11330-11335. IF: 9.040

4. Kramer, B., **Huber, M.**, Kern, C., Klingel, K., Kandolf, R., and Selinka, H.-C. (1997). *Chinese hamster ovary cells are nonpermissive towards infection with coxsackievirus B3 despite functional virus-receptor interactions.*

**Virus Research** 48: 149-156. IF: 1.822

3. **Huber, M.**, Selinka, H.-C., and Kandolf, R. (1997). *Tyrosine phosphorylation events during coxsackievirus B3 replication.*

**The Journal of Virology** 71: 595-600. IF: 6.194

2. Raab de Verdugo, U., Selinka, H.-C., **Huber, M.**, Kramer, B., Kellermann, J., Hofschneider, P. H., and Kandolf, R. (1995). *Characterization of a 100 kDa binding protein for the six serotypes of coxsackie B viruses.*

**The Journal of Virology** 69: 6751-6757. IF: 6.254

1. Stolz, B., **Huber, M.**, Housley, Z., and Erni, B. (1993). *The mannose transporter of Escherichia coli: Structure and function of the IIAB<sup>Man</sup> subunit.*

**The Journal of Biological Chemistry** 268: 27094-27099. IF: 6.733

## Übersichtsartikel, Buchkapitel und Kommentare

26. Esser, P. R., **Huber, M.**, and Martin, S. F. (2023). *ER stress and the inflammatory response in allergic contact dermatitis*.  
**European Journal of Immunology**, 53: e2249984. IF: 6.688
25. **Huber, M.** and Capellmann, S. (2022). *Crosslinking-mediated activation of the FcεRI: does it need antigen for success?*  
**BioCell**, 46:1125-1129. IF: 1.254
24. Kuhny, M. and **Huber, M.** (2020). *The LncRNA, the phosphatase, and the macrophage: can they team up for support in inflammatory diseases?*  
**Annals Translational Medicine**, 8: 1536. IF: 3.297
23. Weiskirchen, R., Meurer, S. K., Liedtke, C., and **Huber, M.** (2019). *Mast cells in liver fibrogenesis*.  
**Cells**, 8:1429. IF: 5.656
22. **Huber, M.**, Cato, A. C. B., Ainooson, G. K., Freichel, M., Tsvilovsky, V., Jessberger, R., Riedlinger, E., Sommerhoff, C. P., and Bischoff, S. C. (2019). *Regulation of the pleiotropic effects of tissue resident mast cells*.  
**Journal of Allergy and Clinical Immunology**, 144 (4S): S31-S45. IF: 13.258  
DOI: <https://doi.org/10.1016/j.jaci.2019.02.004>
21. Hildenbrand, B. and **Huber, M.** (2016). *Immuntherapie in der Onkologie*.  
**Onkologische Pflege**, 2: 53-60.
20. **Huber, M.** (2015). Identify the inhibitors ... and activate them.  
**International Journal of Allergy Medications**, 1: 005e.
19. **Huber, M.** and Gibbs, B. (2015). *SHIP1 and the negative control of mast cell/basophil activation by supra-optimal antigen concentrations*.  
**Molecular Immunology**, 63: 32-37. IF: 2.645
18. Kuhny, M., Zorn, C. N., and **Huber, M.** (2014). *Regulation of FcεRI signaling by lipid phosphatases*.  
**Current Topics in Microbiology and Immunology**, 382: 111-127. IF: 4.86
17. **Huber, M.** (2013). *Microfilaments make mast cells migrate (rather than degranulate)*. Commentary on Smrz et al.  
**The European Journal of Immunology**, 43: 1698-1701. IF: 4.97
16. **Huber, M.** (2013). *Activation/Inhibition of mast cells by supra-optimal antigen concentrations*.  
**Cell Communication and Signaling**, 11:7. IF: 5.50
15. Müller-Hübenthal, B., Azemar, M., Lorenzen, D., **Huber, M.**, Freudenberg, M. A., Galanos, C., Unger, C., and Hildenbrand, B. (2009). *Tumour biology: Tumour-associated inflammation versus antitumour immunity*.

**Anticancer Research**, 29: 4795-4806. IF: 1.390

14. Freudenberg, M. A., Tchaptchet, S., Keck, S., Feyer, G., **Huber, M.**, Schütze, N., and Galanos, C. (2008). *Lipopolysaccharide sensing, an important factor in the innate immune response to Gram-negative bacterial infections. Benefits and hazards of LPS hypersensitivity.*

**Immunobiology**, 213: 193-203. IF: 2.886

13. Brummer, T., Elis, W., Reth, M., and **Huber, M.** (2004). *B cell signal transduction: Tyrosine phosphorylation, kinase activity and calcium mobilization.*

**Methods in Molecular Biology**; Rajewsky, K., and Gu, H. (Eds.); Humana Press, Vol. 271: 189-212.

12. Kalesnikoff, J., Sly, L. M., Hughes, M. R., Buchse, T., Rauh, M. J., Cao, L. P., Lam, V., Mui, A., **Huber, M.**, and Krystal, G. (2003). *The role of SHIP in cytokine-induced signaling.*

**Reviews in Physiology, Biochemistry and Pharmacology**, 149: 87-103. IF: 5.615

11. Reth, M., and **Huber, M.** (2003). *Structure and function of B cell antigen receptor complexes.*

**Handbook of Cell Signaling**; Bradshaw, R., and Dennis, E. (Eds.); Academic Press, p. 327-330.

10. **Huber, M.**, Kalesnikoff, J., Reth, M., and Krystal, G. (2002). *The role of SHIP in mast cell degranulation and IgE-induced mast cell survival.*

**Immunology Letters** 82: 17-21. IF: 2.900

9. **Huber, M.**, Damen, J. E., Ware, M., Hughes, M., Helgason, C. D., Humphries, R. K., and Krystal, G. (2000). *Regulation of mast cell degranulation by SHIP.*

**Mast cells and basophils**; Marone, G., Lichtenstein, L. M., and Galli, S. J. (Eds.); Academic Press, p. 169-182.

8. **Huber, M.** (2000). *Organization of complex situations in the immune system.*

**EMBO Reports** 1: 308-312. IF: 6.460

7. **Huber, M.** (2000). *Signal processing through protein complexes.*

**Boehringer Ingelheim Fonds FUTURA** 15: 165-175.

6. Klingel, K., Selinka, H.-C., **Huber, M.**, Sauter, M., Leube, M., and Kandolf, R. (2000). *Molecular pathology and structural features of enteroviral replication: Toward understanding the pathogenesis of viral heart disease.*

**Herz** 25: 216-220. IF: 0.865

5. Krystal, G., Damen, J. E., Helgason, C. D., **Huber, M.**, Hughes, M. R., Kalesnikoff, J., Lam, V., Rosten, P., Ware, M. D., Yew, S., and Humphries, R. K. (1999). *SHIPs ahoy.*

**The International Journal of Biochemistry and Cell Biology** 31: 1007-1010. IF: 1.585

4. **Huber, M.**, Helgason, C. D., Damen, J. E., Scheid, M., Duronio, V., Lam, V., Humphries, R. K., and Krystal, G. (1999). *The role of SHIP in FcεR1-induced signalling.*

**Current Topics in Microbiology and Immunology** 244: 29-42. IF: 2.416

3. **Huber, M.**, Helgason, C. D., Damen, J. E., Scheid, M., Duronio, V., Liu, L., Ware, M. D., Humphries, R. K., and Krystal, G. (1999). *The role of SHIP in growth factor induced signalling.*

**Progress in Biophysics and Molecular Biology** 71: 423-434. IF: 4.794

2. Selinka, H.-C., **Huber, M.**, Pasch, A., Klingel, K., Aepinus, C., and Kandolf, R. (1998). *Coxsackie B virus and its interaction with permissive host cells.*

**Clinical and Diagnostic Virology** 9: 115-123. IF: 0.520

1. Selinka, H.-C., Klingel, K., **Huber, M.**, Kramer, B., Kämmerer, U., and Kandolf, R. (1996). *Molecular pathogenesis of myocarditis and cardiomyopathy: Analysis of virus-receptor interactions and tyrosine phosphorylation events.*

**The role of immune mechanisms in cardiovascular disease**; Schultheiß, H. P. and Schwimmbeck, P. (Eds.); Springer Verlag, p. 17-26.